Differential Expression of AURKA, AURKB, and PLK1 Modulates Clinical Outcomes and Survival in Acute Myeloid Leukemia
Authors:
- Anna Karolyna da Costa MachadoAMAnna Karolyna da Costa Machado
- Beatriz Maria Dias NogueiraBNBeatriz Maria Dias Nogueira
- Deivide de Sousa OliveiraDODeivide de Sousa Oliveira
- Caio Bezerra MachadoCMCaio Bezerra Machado
- Flávia Melo Cunha de Pinho PessoaFPFlávia Melo Cunha de Pinho Pessoa
- Leidivan Sousa CunhaLCLeidivan Sousa Cunha
- Igor Valentim BarretoIBIgor Valentim Barreto
- Isabelle Magalhães FariasIFIsabelle Magalhães Farias
- Rodrigo Monteiro RibeiroRRRodrigo Monteiro Ribeiro
- Ana Paula Lopes MoreiraAMAna Paula Lopes Moreira
- Kaira Mara Cordeiro de AlbuquerqueKAKaira Mara Cordeiro de Albuquerque
- Mateus de Paula GomesMGMateus de Paula Gomes
Open Access
- 3 December 2025
- journal article
- research article
- Published by MDPI AG in Kinases and Phosphatases
- Vol. 3 (4) , 25
Abstract
Acute myeloid leukemia (AML) is one of the most aggressive types of leukemia, represented by the clonal proliferation of hematopoietic precursors, which mainly promotes quantitative and differentiation alterations, as well as normal hematopoiesis suppression. Throughout leukemogenesis, modifications may occur in several elements that make up cellular signaling pathways; among these, AURKA, AURKB, and PLK1 are key related regulators of mitotic progression and cellular proliferation. This study investigated the hematological profile and the expression of the AURKA, AURKB, and PLK1 genes in a cohort of individuals with AML, in order to understand their roles in the pathophysiology of the disease. The analyses revealed a significant hypoexpression of AURKA in the bone marrow of AML individuals compared to the control group (p = 0.0254) and AURKB showed no significant difference in bone marrow and peripheral blood samples. It was also observed a hyperexpression of PLK1 in bone marrow (p < 0.0001) and in peripheral blood (p = 0.0144). Our results also point to PLK1 as a potential biomarker for AML, since its hyperexpression did not differ with respect to gender, risk stratification, or age of the individuals. Finally, survival analyses indicate that AURKA expression in the bone marrow is associated with a protective factor and increased survival, and that those with higher expression of the three target genes had a lower mortality rate (p = 0.043).Keywords
Funding Information
- Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (88887.907990/2023-00, 88887.804627/2023-00, 88887.964125/2024-00, 88887.902891/2023-00)
- National Council of Technological and Scientific Development (404213/2021-9)
- Cearense Foundation of Scientific and Technological Support (BMD-0008-02399.01.11/25, BMD-0008-01438.01.33/25)
This publication has 75 references indexed in Scilit:
- Emerging roles of Aurora-A kinase in cancer therapy resistanceActa Pharmaceutica Sinica B, 2023
- Acute myeloid leukemia: 2023 update on diagnosis, risk‐stratification, and managementAmerican Journal of Hematology, 2023
- Sex differences in adults with acute myeloid leukemia and the impact of sex on overall survivalCancer Medicine, 2022
- Comprehensive analysis of PLKs expression and prognosis in breast cancerCancer Genetics, 2022
- Emerging role of let-7 family in the pathogenesis of hematological malignanciesBiomedicine & Pharmacotherapy, 2021
- Reversine exerts cytotoxic effects through multiple cell death mechanisms in acute lymphoblastic leukemiaCellular Oncology, 2020
- Protein targeting chimeric molecules specific for dual bromodomain 4 (BRD4) and Polo-like kinase 1 (PLK1) proteins in acute myeloid leukemia cellsBiochemical and Biophysical Research Communications, 2020
- Epidemiology of acute myeloid leukemia: Recent progress and enduring challengesBlood Reviews, 2019
- Inhibition of Aurora kinases induces apoptosis and autophagy via AURKB/p70S6K/RPL15 axis in human leukemia cellsCancer Letters, 2016
- Aurora A, MCAK, and Kif18b promote Eg5-independent spindle formationChromosoma, 2016